Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-13
2005-09-13
Davis, Zinna Northington (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S183000, C514S327000, C514S329000, C514S330000, C514S331000, C540S450000, C540S482000, C540S484000, C540S609000, C540S612000, C546S192000, C546S216000, C546S219000, C546S220000, C546S221000, C546S223000, C546S224000, C546S225000, C546S227000, C546S229000, C546S232000
Reexamination Certificate
active
06943177
ABSTRACT:
Cis-2,6-disubstituted piperdine analogs, or lobeline analogs, having the general formula:are used to treat diseases of the central nervous system, drug abuse and withdrawal therefrom as well as to treating eating disorders.
REFERENCES:
patent: 5414005 (1995-05-01), Schneider et al.
patent: 5486362 (1996-01-01), Kitchell et al.
patent: 5830904 (1998-11-01), Crooks et al.
patent: 6087376 (2000-07-01), Crooks et al.
patent: 6455543 (2002-09-01), Dwoskin et al.
patent: 6703406 (2004-03-01), Crooks et al.
patent: 2 528 834 (1982-06-01), None
patent: WO 01/08678 (2001-02-01), None
The Practice of Medicinal Chemistry, Camille G. Wermuth, Academic Press, 1996, pp. 204-205.
The Condensed Chemical Dictioary, 1956, Fifth Edition, p. 110.
Database CAS on STN, (Columbus, OH, USA) Accession No. 103: 488116 “Lobelanine” CS217195, (1982).
Database CAS on STN, (Columbus, OH, USA) ACCESSION No. 123:37615 Schiffrin et al. “Electroassisted separation of metals by solvent extraction and supported-liquid memberanes”, HYDROMETALL. '94, Int. symp. (1994).
Database CAS on STN, (Columbus, OH, USA) ACCESSION No. 66:22229, Kracmar et al. “Ultraviolet spectrophotometry in the control of drugs” Pharmazie (1996).
Database CAS on STN, (Columbus, OH, USA) ACCESSION No. 72:65748, Schoenenberger et al. “Action mechanism of antimicrobial beta-amino ketones”, Phar. Acta helv.(1996) vol. 44, No. 11, pp. 691-714
Database CAS on STN, (Columbus, OH, USA) ACCESSION No. 128:270483, Katritzky et al. “A short asymmetric synthesis of 2,5-disubstituted pyrrolidines”, Tetrahedron Lett (1998) vol. 39, pp. 1698-1700.
P. Crooks et al. “Inhibition of Nicotine Evoked [3H ]Dopamine Release by Pyridino N-Substituted Nicotine Analogues: A New Class of Nicotinic Antagonist” Drug Development Research. 1995. 36:91-102.
L. Teng et al. “Lobeline Displaces [3H ] Dihydrotetrabenazine Binding and Releases [3H ] Dopamine from Rat Striatal Synaptic Vesicles: Comparison withd-Amphetamine” Journal of Neurochemistry. vol. 71. No. 1. Jul. 1998. 258-265.
L. Teng et al. “Lobeline and Nicotine Evoke [3H ] Overflow from Rat Striatal Slices Preloaded with [3H ] Dopamine: Differential Inhibition of Synaptosomal and Vesicular [3H ] Domapine Uptake” The Journal of Pharmacology and Experimental Therapeutics. Williams & Wilkins. vol. 280. No. 3. 1997. 1432-1444.
Y. Cheng et al. “Relationship between the inhibition constant (K1) and the concentration of inhibitor which casuses 50 per cent inhibition (I50) of an enzymatic reaction” Biochemical Pharmacology. vol. 22, No. 23. Dec. 1, 1973. 3099-3108.
Michael Decker et al. “Effects of Lobeline, a Nicotinic Receptor Agonist, on Learning and Memory” Pharmacology Biochemistry and Behavior. vol. 45. 1993. 571-576.
Carmelo Romano et al. “Stereospecific Nicotine Receptors on Rat Brain Membranes” Science. vol. 210. Nov. 7, 1980. 647-650.
S. Hamann et al. “Hyperalgesic and Analgesic Actions of Morphine, U50-488, Naltrexone, and (-)-Lobeline in the Rat Brainstem” Pharmacology Biochemistry and Behavior. vol. 47. 1993. 197-201.
Dennis K. Miller et al. “Lobeline inhibits nicotine-evoked [9H ]dopamine overflow from rat striatal slices and nicotine-evoked86Rb+efflux from thalamic synaptosomes” Neuropharmacology. 2000. 39:2654-2662.
Patrick M. Lippiello et al. “The Binding of L-[3H ] Nicotine to a Single Class of High Affinity Sites in Rat Brain Membranes” Molecular Pharmacology. 29:448-454.
L. Dwoskin et al. “Robust Modulation of [3H ] Dopamine Release from Rat Striatal Slices by D-2 Dopamine Receptors” The Journal of Pharmacology and Experimental Therapeutics. 1996. vol. 239. No. 2. 442-453.
M. Marks et al. “Nicotonic Binding Sites in Rat and Mouse Brain: Comparison of Acetylcholine, Nicotine, and α-Bungarotoxin” Molecular Pharmacology. 30:427-436.
E. Broussolle et al. “In Vivo Specific Binding of [3H ]1-Nicotine in the Mouse Brain”Life Sciences. 1989. vol. 44. 1123-1132.
L. Dwoskin et al. “(S)-(-)-Cotinine, the Major Brain Metabolite of Nicotine, Stimulates Nicotonic Receptors to Evoke [3H ] Dopamine Release from Rat Striatal Slices in Calcium-Dependent Manner” The Journal of Pharmacology and Experimental Therapeutics. 1999. vol. 288. No. 2. 905-911.
R.B. Barlow et al. “Relations between structure and nicotine-like activity: X-ray crystal structure analysis of (-)-cytisine and (-)-lobeline hydrochloride and a comparison with (-)-nicotine and other nicotine-like compounds” Br. Journal of Pharmacology. 1989. vol. 98. 799-808.
P.B.S. Clarke & M. Reuben. “Release of [3H ]-noradrenaline from rat hippocampal synaptosomes by nicotine: mediation by different nicotinic receptor subtypes from striatal [3H]-dopamine release” British Journal of Pharmacology. 1996. 117. 595-606.
M. Bradford, “A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding” Analytical Biochemistry. 1976. 72. 248-254.
Crooks Peter A.
Dwoskin Linda P.
Jones Marlon D.
Davis Zinna Northington
McDermott Will & Emery LLP
University of Kentucky Research Foundation
LandOfFree
Cis-2,6-disubstituted piperidines for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cis-2,6-disubstituted piperidines for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cis-2,6-disubstituted piperidines for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3384465